[go: up one dir, main page]

WO2010005303A3 - Nouveaux indicateurs de longévité humaine et du taux de vieillissement biologique - Google Patents

Nouveaux indicateurs de longévité humaine et du taux de vieillissement biologique Download PDF

Info

Publication number
WO2010005303A3
WO2010005303A3 PCT/NL2009/050409 NL2009050409W WO2010005303A3 WO 2010005303 A3 WO2010005303 A3 WO 2010005303A3 NL 2009050409 W NL2009050409 W NL 2009050409W WO 2010005303 A3 WO2010005303 A3 WO 2010005303A3
Authority
WO
WIPO (PCT)
Prior art keywords
longevity
genetic
methods
markers
genetic markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2009/050409
Other languages
English (en)
Other versions
WO2010005303A2 (fr
Inventor
Pieternella Slagboom
Rudolf Gerardus Johannes Westendorp
Jeanne Jacobine Houwing - Duistermaat
Bastiaantheodoor Heijmans
Marian Beekman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden HODN
Original Assignee
Leids Universitair Medisch Centrum LUMC
Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden HODN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC, Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden HODN filed Critical Leids Universitair Medisch Centrum LUMC
Publication of WO2010005303A2 publication Critical patent/WO2010005303A2/fr
Publication of WO2010005303A3 publication Critical patent/WO2010005303A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des marqueurs génétiques et biochimiques de longévité, qui ont été identifiés comme variation génétique commune associée à la longévité dans des cohortes de sujets âgés. Les marqueurs génétiques de longévité de l’invention concernent en particulier une collection de molécules d’acide nucléique comprenant une séquence de nucléotides qui est en déséquilibre de liaison avec un SNP associé à la longévité dans des cohortes de sujets âgés. Dans un autre mode de réalisation de l’invention, les marqueurs génétiques de longévité sont des molécules d’acide nucléique qui comprennent des séquences de nucléotides qui sont exprimées différemment entre une population qui exprime une survie en excès et une population témoin. L’invention concerne, dans un autre aspect, un portefeuille comprenant des sous-ensembles des marqueurs génétiques de longévité. Les marqueurs génétiques de longévité de l’invention peuvent être utilisés dans des procédés de détermination de la prédisposition génétique à la longévité, des procédés de criblage d’une substance qui module le taux de vieillissement biologique ou une substance qui est capable de modulation de la longévité et/ou de l’espérance de vie, et/ou des procédés d’évaluation de l’âge physiologique.
PCT/NL2009/050409 2008-07-07 2009-07-07 Nouveaux indicateurs de longévité humaine et du taux de vieillissement biologique Ceased WO2010005303A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159827 2008-07-07
EP08159827.8 2008-07-07

Publications (2)

Publication Number Publication Date
WO2010005303A2 WO2010005303A2 (fr) 2010-01-14
WO2010005303A3 true WO2010005303A3 (fr) 2010-04-29

Family

ID=39938277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2009/050409 Ceased WO2010005303A2 (fr) 2008-07-07 2009-07-07 Nouveaux indicateurs de longévité humaine et du taux de vieillissement biologique

Country Status (1)

Country Link
WO (1) WO2010005303A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048785A2 (fr) * 1997-04-29 1998-11-05 Kenneth Blum, Inc. Diagnostic d'un syndrome d'insatisfaction a l'aide de polygene allelique et traitement associe
WO2002014552A2 (fr) * 2000-08-11 2002-02-21 Children's Medical Center Corporation Loci genetiques indicateurs de la propension a la longevite et procedes d'identification de la propension a la resistance aux maladies liees a l'age
WO2004050898A2 (fr) * 2002-12-04 2004-06-17 Elixir Pharmaceuticals, Inc. Composants de la voie ampk
US20040259104A1 (en) * 2002-10-22 2004-12-23 Lamberts Steven Willem Jan Test
US20060068432A1 (en) * 2003-03-20 2006-03-30 Nir Barzilai Biological markers for longevity and diseases and uses thereof
US20070161022A1 (en) * 2005-11-30 2007-07-12 Kim Stuart K Signatures for human aging
WO2007131345A1 (fr) * 2006-05-12 2007-11-22 The Hospital For Sick Children Facteur de risque génétique dans les gènes sod1 et sfrs15 dans la néphropathie, la cataracte diabétique, la maladie cardiovasculaire et la longévité

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048785A2 (fr) * 1997-04-29 1998-11-05 Kenneth Blum, Inc. Diagnostic d'un syndrome d'insatisfaction a l'aide de polygene allelique et traitement associe
WO2002014552A2 (fr) * 2000-08-11 2002-02-21 Children's Medical Center Corporation Loci genetiques indicateurs de la propension a la longevite et procedes d'identification de la propension a la resistance aux maladies liees a l'age
US20040259104A1 (en) * 2002-10-22 2004-12-23 Lamberts Steven Willem Jan Test
WO2004050898A2 (fr) * 2002-12-04 2004-06-17 Elixir Pharmaceuticals, Inc. Composants de la voie ampk
US20060068432A1 (en) * 2003-03-20 2006-03-30 Nir Barzilai Biological markers for longevity and diseases and uses thereof
US20070161022A1 (en) * 2005-11-30 2007-07-12 Kim Stuart K Signatures for human aging
WO2007131345A1 (fr) * 2006-05-12 2007-11-22 The Hospital For Sick Children Facteur de risque génétique dans les gènes sod1 et sfrs15 dans la néphropathie, la cataracte diabétique, la maladie cardiovasculaire et la longévité

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AKATSUKI KOKAZE ET AL: "Longevity-associated mitochondrial DNA 5178 C/A polymorphism and its interaction with cigarette consumption are associated with pulmonary function in middle-aged Japanese men", JOURNAL OF HUMAN GENETICS, SPRINGER-VERLAG, TO, vol. 52, no. 8, 17 July 2007 (2007-07-17), pages 680 - 685, XP019520274, ISSN: 1435-232X *
CAPRI ET AL: "Human longevity within an evolutionary perspective: The peculiar paradigm of a post-reproductive genetics", EXPERIMENTAL GERONTOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 43, no. 2, 17 January 2008 (2008-01-17), pages 53 - 60, XP022424984, ISSN: 0531-5565 *
DATABASE EMBL [online] 16 May 2001 (2001-05-16), "602723676T1 NIH_MGC_113 Homo sapiens cDNA clone IMAGE:4849987 3', mRNA sequence.", XP002554551, retrieved from EBI accession no. EMBL:BG746166 Database accession no. BG746166 *
DATABASE EMBL [online] 29 December 1999 (1999-12-29), "xr04c06.x1 NCI_CGAP_Brn53 Homo sapiens cDNA clone IMAGE:2759146 3', mRNA sequence.", XP002554550, retrieved from EBI accession no. EMBL:AW264502 Database accession no. AW264502 *
IMUSCE FRANCESCHI ET AL: "The extreme longevity: The state of the art in Italy", EXPERIMENTAL GERONTOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 43, no. 2, 17 January 2008 (2008-01-17), pages 45 - 52, XP022424983, ISSN: 0531-5565 *
REINER ET AL: "Common promoter polymorphisms of inflammation and thrombosis genes and longevity in older adults: The cardiovascular health study", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 181, no. 1, 1 July 2005 (2005-07-01), pages 175 - 183, XP005270342, ISSN: 0021-9150 *

Also Published As

Publication number Publication date
WO2010005303A2 (fr) 2010-01-14

Similar Documents

Publication Publication Date Title
Tavallaie et al. Toward biosensors for the detection of circulating microRNA as a cancer biomarker: an overview of the challenges and successes
Bouchard Genomic predictors of trainability
Yildiz et al. Naked eye detection of lung cancer associated miRNA by paper based biosensing platform
Xie et al. A DNA tetrahedron-based molecular beacon for tumor-related mRNA detection in living cells
NZ577805A (en) Genetic markers for risk management of cardiac arrhythmia
WO2007041340A3 (fr) Cellules microfluidiques a arrangements paralleles de molecules d'adn individuelles
NZ593628A (en) Genetic variants useful for risk assessment of thyroid cancer using rs944289
WO2005007830A3 (fr) Procedes et compositions pour diagnostic, stadage et pronostic du cancer de la prostate
WO2006110855A3 (fr) Procedes de determination de variantes de sequence utilisant un sequencage des amplicons
ATE515488T1 (de) Click-chemie zur herstellung von reportermolekülen
WO2005114190A3 (fr) Procedes pour identifier des marqueurs biologiques
WO2009009752A3 (fr) Modèles génétiques pour le classement des risques de cancer
ATE515577T1 (de) Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen
WO2008070144A3 (fr) Gènes soumis à empreinte et maladies
WO2008132763A3 (fr) Variantes génétiques d'évaluation de la prédisposition aux maladie des artères coronaires et à l'infarctus du myocarde
EP3219813A3 (fr) Procédés pour traiter, diagnostiquer, et surveiller le lupus
Rong et al. Hydrogen peroxide detection with high specificity in living cells and inflamed tissues
CA2602635C (fr) Procede de modification de la specificite de liaison de proteines par reactions d'oxydoreduction
WO2007016532A3 (fr) Mutations et polymorphismes de hdac4
WO2010005303A3 (fr) Nouveaux indicateurs de longévité humaine et du taux de vieillissement biologique
Ghasemi et al. Improvements to direct quantitative analysis of multiple microRNAs facilitating faster analysis
MX2010002993A (es) Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico.
WO2008065544A3 (fr) Prédicteurs génétiques d'un risque de diabète sucré de type 2
JP2013526869A5 (fr)
Zhang et al. A rapid bioanalytical tool for detection of sequence-specific circular DNA and mitochondrial DNA point mutations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09788216

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09788216

Country of ref document: EP

Kind code of ref document: A2